Vivesto AB (VIVE) - Total Assets
Based on the latest financial reports, Vivesto AB (VIVE) holds total assets worth Skr177.85 Million SEK (≈ $19.14 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Vivesto AB to assess how comfortably operating cash covers total debt obligations.
Vivesto AB - Total Assets Trend (2004–2025)
This chart illustrates how Vivesto AB's total assets have evolved over time, based on quarterly financial data. See VIVE net asset value for net asset value and shareholders' equity analysis.
Vivesto AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Vivesto AB's total assets of Skr177.85 Million consist of 3.7% current assets and 96.3% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 1.4% |
| Accounts Receivable | Skr3.40 Million | 2.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr143.24 Million | 96.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Vivesto AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VIVE stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivesto AB's current assets represent 3.7% of total assets in 2025, a decrease from 6.8% in 2004.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2025, down from 5.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 96.0% of total assets, an increase from 92.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 96.1% of total assets.
Vivesto AB Competitors by Total Assets
Key competitors of Vivesto AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Vivesto AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.06 | 1.45 | 1.68 |
| Quick Ratio | 3.06 | 1.45 | 1.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr23.25 Million | Skr9.41 Million | Skr117.39 Million |
Vivesto AB - Advanced Valuation Insights
This section examines the relationship between Vivesto AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.58 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -13.8% |
| Total Assets | Skr149.04 Million |
| Market Capitalization | $10.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vivesto AB's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vivesto AB's assets decreased by 13.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vivesto AB (2004–2025)
The table below shows the annual total assets of Vivesto AB from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr149.04 Million ≈ $16.04 Million |
-13.79% |
| 2024-12-31 | Skr172.88 Million ≈ $18.60 Million |
-21.66% |
| 2023-12-31 | Skr220.67 Million ≈ $23.75 Million |
-37.99% |
| 2022-12-31 | Skr355.88 Million ≈ $38.30 Million |
-40.12% |
| 2021-12-31 | Skr594.31 Million ≈ $63.96 Million |
-31.18% |
| 2020-12-31 | Skr863.54 Million ≈ $92.93 Million |
-14.11% |
| 2019-12-31 | Skr1.01 Billion ≈ $108.19 Million |
+55.54% |
| 2018-12-31 | Skr646.38 Million ≈ $69.56 Million |
+13.78% |
| 2017-12-31 | Skr568.08 Million ≈ $61.13 Million |
+8.91% |
| 2016-12-31 | Skr521.58 Million ≈ $56.13 Million |
+1.16% |
| 2015-12-31 | Skr515.58 Million ≈ $55.48 Million |
+0.20% |
| 2014-12-31 | Skr514.57 Million ≈ $55.38 Million |
+9.86% |
| 2013-12-31 | Skr468.38 Million ≈ $50.41 Million |
+5.21% |
| 2012-12-31 | Skr445.18 Million ≈ $47.91 Million |
+27.26% |
| 2011-12-31 | Skr349.81 Million ≈ $37.64 Million |
+9.21% |
| 2010-12-31 | Skr320.32 Million ≈ $34.47 Million |
+78.30% |
| 2009-12-31 | Skr179.65 Million ≈ $19.33 Million |
+85.02% |
| 2008-12-31 | Skr97.10 Million ≈ $10.45 Million |
+10.75% |
| 2007-12-31 | Skr87.67 Million ≈ $9.43 Million |
-27.42% |
| 2006-12-31 | Skr120.79 Million ≈ $13.00 Million |
+89.64% |
| 2005-12-31 | Skr63.69 Million ≈ $6.85 Million |
+76.63% |
| 2004-12-31 | Skr36.06 Million ≈ $3.88 Million |
-- |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantri… Read more